Clinical Trial Update: Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR [Phase 3]

View source ↗

Summary

Phase 3 safety study comparing FSME IMMUN NEW with ENCEPUR in volunteers aged 16 to 65 for tick-borne encephalitis; the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tick-borne Encephalitis

Drugs mentioned

• Encepur (Tick-borne encephalitis vaccine (inactivated))
• FSME IMMUN NEW (Tick-borne encephalitis vaccine (inactivated))

Snippet

Sponsor: Pfizer | Conditions: Encephalitis, Tick-borne | Phase 3 | Status: COMPLETED